Home › Lupus Nephritis
Pag-aaral pangklinika para sa Lupus Nephritis na nagre-recruit sa U.S.
34 pag-aaral para sa Lupus Nephritis ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY10 pag-aaral
- Atlanta, GA9 pag-aaral
- Chicago, IL9 pag-aaral
- Durham, NC9 pag-aaral
- Houston, TX8 pag-aaral
- Boston, MA7 pag-aaral
- San Francisco, CA7 pag-aaral
- Philadelphia, PA6 pag-aaral
- St. Louis, MO5 pag-aaral
- Miami, FL5 pag-aaral
- Dallas, TX4 pag-aaral
- Gainesville, FL4 pag-aaral
- Syracuse, NY4 pag-aaral
- Charleston, SC4 pag-aaral
- Aurora, CO4 pag-aaral
- Charlotte, NC4 pag-aaral
- Washington, DC3 pag-aaral
- Columbus, OH3 pag-aaral
- Johns Creek, GA3 pag-aaral
- Cincinnati, OH3 pag-aaral
- Worcester, MA3 pag-aaral
- Los Angeles, CA3 pag-aaral
- Baltimore, MD3 pag-aaral
- Jacksonville, FL3 pag-aaral
- Cleveland, OH3 pag-aaral
- Santa Monica, CA3 pag-aaral
Ayos sa estado
- Arizona3 pag-aaral
- California14 pag-aaral
- Colorado6 pag-aaral
- Florida11 pag-aaral
- Georgia11 pag-aaral
- Illinois9 pag-aaral
- Louisiana4 pag-aaral
- Maryland5 pag-aaral
- Massachusetts8 pag-aaral
- Michigan3 pag-aaral
- Minnesota3 pag-aaral
- Missouri6 pag-aaral
- New Jersey5 pag-aaral
- New York15 pag-aaral
- North Carolina12 pag-aaral
- Ohio7 pag-aaral
- Pennsylvania6 pag-aaral
- South Carolina5 pag-aaral
- Tennessee4 pag-aaral
- Texas11 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 18 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07931170Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06711887Dapagliflozin in Active Lupus Nephritis
Nagre-recruitPhase 4
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07323524Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06434363A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Nagre-recruitPhase 2
Edad 5 hanggang 17 · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05039619A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Nagre-recruitPhase 1
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07085104Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Nagre-recruitPhase 2
Edad 12 hanggang 65 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07053800Study of Systemic Lupus Erythematosus
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 3 hanggang 120 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT00001372Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Nagre-recruitPhase 1
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT06975787A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06925542Lupus Nephritis Care Pathway
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT07783152RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Nagre-recruitPhase 1/2
Edad 12 hanggang 65 · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT06121297A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Nagre-recruitPhase 2
Edad 16 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06419205CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Nagre-recruitPhase 1/2
Edad 10 hanggang 29 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Nagre-recruitPhase 2
Edad 16 hanggang 70 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Nagre-recruitPhase 2
Edad 8 hanggang 20 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Nagre-recruitPhase 2
Edad 12 hanggang 70 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Nagre-recruitPhase 1/2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 10, 2026 · NCT06897930PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Nagre-recruitPhase 4
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT07611214A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Kababaihan · Na-update Hul 24, 2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT06527872US Zamto-cel Autoimmune Diseases
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT06708845Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.